Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
April 22, 2019
- SanBio Vows to Create In-House Marketing System in Japan by 2020, Eyes Global Leader by 2025: President
April 22, 2019
- Sumitomo Dainippon Cuts Sales Outlook for FY2018, Ups Profit Forecast
April 22, 2019
- Novartis to Begin Kymriah Treatment at 2-3 Japan Sites, Looks at Gradual Expansion
April 19, 2019
- Boehringer to Remain Major Employer in Japan with As-Needed Staffer Placement
April 19, 2019
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
- Pfizer Japan Mulls Over Alternative Manufacturing Route Following Suspension of Methotrexate Production in Germany
April 19, 2019
- SanBio Unveils Positive PII Data for SB623 in Traumatic Brain Injury
April 18, 2019
- Sanofi Pushing Drugs’ Added Values to Secure Patient Access amid Rising Awareness for Economic Efficiency
April 18, 2019
- Bayer, Hokkaido Pref. Join Forces to Tackle Life Style Diseases
April 18, 2019
- Japan Pharma Market Grew 87.1% in 30 Years of Heisei Era: IQVIA
April 18, 2019
- With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
- Evenity Heavily Pitched via In-Clinic Seminars in February: Anterio
April 17, 2019
- Toa Eiyo Grants China Marketing Rights for Bisono Tape to Local Firm
April 17, 2019
- Nihon Generic to Mount Aggressive Sales Campaigns Taking Advantage of Group Synergy
April 16, 2019
- Takeda Nabs Top Japanese Analyst for Global IR Team
April 16, 2019
- Mitsubishi Tanabe ALS Drug Accepted for Review in China
April 16, 2019
- Daiichi Sankyo’s Lyrica Contender Tarlige Now Available
April 16, 2019
- Bayer Japan Ethical Drug Sales Slip 1% in 2018
April 15, 2019
- AstraZeneca Japan on Track for 4 Launches in 2019, Dependence on Crestor Fades
April 15, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…